{
    "clinical_study": {
        "@rank": "148134", 
        "arm_group": {
            "arm_group_label": "Radiation", 
            "arm_group_type": "Experimental", 
            "description": "To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy"
        }, 
        "brief_summary": {
            "textblock": "To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide\n      on survival and quality of life in elderly, poor performance status  patients with newly\n      diagnosed  HGG."
        }, 
        "brief_title": "Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "detailed_description": {
            "textblock": "Investigators designed  this study  with the aim  to assess the effect of IMRT using VMAT\n      rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in\n      elderly, poor performance status  patients with newly diagnosed  HGG.  The potential\n      advantage of this approach is deliver a more selective irradiation to tumor's target with\n      reducing the dose to normal brain and to allow the delivery of a higher dose, optimizing the\n      therapeutic window."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged \u2265 70 years\n\n          -  Karnosky performance status (KPS) \u226460\n\n          -  Histologically confirmed  HGG after tumor biopsy\n\n               -  GBM\n\n               -  Anaplastic Astrocytoma\n\n               -  Anaplastic Oligoastrocytoma\n\n               -  Anaplastic Oligodendroglioma without IDH1 mutation and no codeletion 1p19q\n\n          -  Estimated survival  \u2265 3 months.\n\n          -  Normal liver, Kidney and bone marrow function\n\n          -  Written informed consent\n\n        Exclusion criteria:\n\n          -  Prior radiation therapy\n\n          -  Other primary cancer\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099487", 
            "org_study_id": "1139"
        }, 
        "intervention": {
            "arm_group_label": "Radiation", 
            "description": "hypofractionated IMRT", 
            "intervention_name": "Radiation", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "HGG", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "piera.navarria@humanitas.it", 
                "last_name": "Piera Navarria, M.D.", 
                "phone": "+390282247458"
            }, 
            "facility": {
                "address": {
                    "city": "Milan", 
                    "country": "Italy", 
                    "state": "Lombardia", 
                    "zip": "20090"
                }, 
                "name": "ICH Humanitas Cancer Center"
            }, 
            "investigator": {
                "last_name": "Marta Scorsetti, Director", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Hypofractionated Imrt (Vmat-Ra) With Temozolomide For Elderly Patients, Unsuitable For Surgery With Newly Diagnosed High Grade Glioma", 
        "other_outcome": [
            {
                "description": "Incidence of hematologic and non hematologic severe toxicities (grade III/ IV) will evaluate using NCI-CTCA scale. Late toxicity will evaluate using CTCA 4.2", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "description": "Quality of Life", 
                "measure": "QoL", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }
        ], 
        "overall_contact": {
            "email": "piera.navarria@humanitas.it", 
            "last_name": "Pierina Navarria, M.D.", 
            "phone": "+3082247458"
        }, 
        "overall_official": {
            "affiliation": "Humanitas Cancer Center", 
            "last_name": "Piera Navarria, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: National Bioethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression free survival", 
            "measure": "PFS", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099487"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istituto Clinico Humanitas", 
            "investigator_full_name": "Michele Tedeschi", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Overall Survival", 
            "measure": "OS", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Istituto Clinico Humanitas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istituto Clinico Humanitas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}